Case Report

First Report on Infant Acute Urticaria after Mother’s Parenteral Use of Meglumine Antimoniate (Glucantime): A Case Report

Omid MOZAFARI 1, 2, Seyed Afshin SHOROFI 3, *Seyde Sedighe YOUSEFI 3

1. Dept. of Traditional Persian Medicine, School of Medicine, Student Research Committe, Mazandaran University of Medical Sciences, Sari, Iran
2. Dept. of Traditional Persian Medicine, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
3. Traditional and Complementary Medicine Research Center, Mazandaran University of Medical Sciences, Sari, Iran

*Corresponding Author: Email: dr_ssyosefi@yahoo.com
(Received 10 May 2016; accepted 10 Aug 2016)

Abstract

Pentavalent antimonials are still the first drug of choice for the treatment of cutaneous leishmaniasis (CL). Like other treatments, they can cause adverse reactions including musculoskeletal pain, gastrointestinal disturbances, and mild to moderate headaches. In this paper, we report the first case of an infant who developed acute urticaria after her mother’s parenteral use of meglumine antimoniate (glucantime).

Keywords: Cutaneous leishmaniasis, Meglumine antimoniate (Glucantime), Adverse reactions

Introduction

Cutaneous leishmaniasis (CL) is a major public health problem in many countries. However, there are many topical and systematic treatments for CL. At present, pentavalent antimonials are still the first drug of choice for the treatment of CL (1). Systemic administration of pentavalent antimonials has been associated with such adverse reactions as musculoskeletal pain, gastrointestinal disturbances, and mild to moderate headaches. "Electrocardiographic QT interval prolongation and a mild to moderate increase in liver and pancreatic enzymes are other adverse effects of pentavalent antimonials" (2,3). Nonetheless, acute urticaria in infants has never been reported to be associated with maternal use.

Here we report a case of an infant presenting with acute urticaria after her mother’s parenteral use of meglumine antimoniate (glucantime) for the first time.

Case Report

In November 2015, a 34-yr-old breast-feeding woman from Gonbad City of Iran presented with a lesion on the anterior region of her abdomen that lasted about 60 days. The lesion first appeared as a small red papule and then progressed to an ulcer. The slowly enlarging lesion had raised borders and was slightly erythematous and crusty. It was a firm, non-tender, well-defined lesion, which measured 4 cm × 3 cm in diameter. The systemic and topical antibiotics and steroids failed to treat the condition. A slit-skin smear from the edge of the ulcer with Giemsa stain showed Leishman bodies within the macrophages, which confirmed the diagnosis of cutaneous leishmaniasis.

The patient was treated with a weekly cryotherapy regimen and intralesional injections of glucantime. The patient was discontented with no sign of improvement with the prescribed medications.
and interventions after three wk. As a result, the
treatment was changed to glucantime at a dose of
20 mg/kg-body weight intramuscularly for two
wk. For our patient weighing 95 kg, we pre-
scribed 3 vials per day for 14 d (according to the
National Guidelines for Leishmaniasis Survei-
lance in Iran -2012). A day after the start of sys-
temic therapy, the patient brought her fifteen-
month-old breast-feed infant with urticaria and
malaise but without cosinophilia (1cells/mm3).
With an elevated liver enzyme SGOT level (46
IU/L, normal range is up to 31 IU/L); the in-
fant’s vital signs were normal. The physical exam-
ination results were normal except for urticaria,
which was dominant on the abdomen, back and
thighs (Fig. 1). Both the mother and the infant
had no history of exposure to any alternative
causes other than glucantime. The mother was
advised to discontinue breastfeeding for two
week and the infant to receive a single dose of
antihistamine (2.5 mg Cetirizine per oral). The
symptoms resolved within 24 h, during which the
urticaria disappeared and malaise was alleviated.
With slow but definite improvement of the le-
sion, the mother reported mild myalgia and ar-
thralgia but otherwise tolerated the glucantime
well.

Discussion

Two pentavalent antimonial drugs, sodium
stibogluconate (Pentostam) and glucantime, have
been the drugs of choice for the treatment of cu-
taneous leishmaniasis for over 50 yr. “In spite of
their wide use for half a century, relatively little is
known about their chemical structures and
mechanism of actions “ (4) and, up until now,
new side effects have been reported as a result of
their use.
In our case, the occurrence of adverse drug re-
action and its successful management after discon-
tinuing the drug points to the unwanted effects
of glucantime as non-pharmacological causes
were not found to have generated the reaction.

We could not find any report of acute urticaria in
infants associated with the mother’s parenteral
use of glucantime.

Fig. 1: Urticaria, obvious on the abdomen, back
and thighs of the patient (Original)

This included a search on LactMed (a TOXNET
database) which led to no records being found
(5). Hence, this is the first reported case of urti-
caria in infants due to the mother’s parenteral use
of glucantime. It is recommended that mothers
discontinue breastfeeding and avoid taking glu-
cantime in systemic doses because of adverse ef-
facts on their infants.

Ethical considerations

Ethical issues (Including plagiarism, informed
consent, misconduct, data fabrication and/or fal-
sification, double publication and/or submission,
redundancy, etc.) have been completely observed by the authors.

Acknowledgments

This manuscript is a part of the PhD thesis of Omid Mozafari (School of Medicine, Mazandaran University of Medical Sciences, approval no. 1751). The authors declare that there is no conflict of interests.

References

1. Mahmoudvand H, Sharifi I, Fasihi Harandi M, Shokohi M, Shakibaie M, Rezaei Rabani T, Jahanbakhsh S, Ghasemi AA (2014). Anti-leishmania effects of methotrexate (MTX) alone and in combination with meglumine antimoniate (MA) against Iranian isolate of sensitive and MA-resistant Leishmania tropica: An invtro assay. Asian Pacific J Trop Med, 4: 412-420.

2. Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A, et al. (2007). Comparison of miltefosine and meglumine antimoniate (GlucantimeR) for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop, 103(1): 33-40.

3. Oliveira LF, Schubach AO, Martins MM, Passos SL, Oliveira RV, Marzochi MC, et al. (2011). Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop, 118(2): 87-96.

4. Roberts WL, McMurray WJ, Rainey PM (1998). Characterization of the antimonial antileishmanial agent meglumine antimonate (glucantime). Antimicrob Agents Chemother, 42(5): 1076-1082.

5. U.S. National Library of Medicine, National Institutes of Health, Health & Human Services: http://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm.